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This study examined factors that predict psychological morbidity and screening adherence in first-degree relatives (FDRs) taking part
in a familial PSA screening study. Prostate cancer patients (index cases – ICs) who gave consent for their FDRs to be contacted for
a familial PSA screening study to contact their FDRs were also asked permission to invite these FDRs into a linked psychosocial study.
Participants were assessed on measures of psychological morbidity (including the General Health Questionnaire; Cancer Worry
Scale; Health Anxiety Questionnaire; Impact of Events Scale); and perceived benefits and barriers, knowledge; perceived risk/
susceptibility; family history; and socio-demographics. Of 255 ICs, 155 (61%) consented to their FDRs being contacted. Of 207 FDRs
approached, 128 (62%) consented and completed questionnaires. Multivariate logistic regression revealed that health anxiety,
perceived risk and subjective stress predicted higher cancer worry (P¼0.05). Measures of psychological morbidity did not predict
screening adherence. Only past screening behaviour reliably predicted adherence to familial screening (P¼0.05). First-degree
relatives entering the linked familial PSA screening programme do not, in general, have high levels of psychological morbidity.
However, a small number of men exhibited psychological distress.
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Despite the mortality and rising incidence from prostate cancers,
screening of the general male population remains controversial
and there is insufficient evidence to recommend screening of the
general male population given the lack of data demonstrating
a mortality reduction (Frankel, 1997; Donovan et al, 2001).
Randomised control trials are underway in Europe and the US.
However, conclusive mortality analyses are not expected until
approximately 2010 (Roobol and Schroder, 2003). In the UK, the
National Health Service does not recommend routine population
PSA screening. However, PSA testing is available for those men
who request it and have been given detailed information in order
to make an informed choice (Department of Health, 2000).
Regardless of uncertainties associated with general population
PSA screening, targeted PSA screening of men at high-risk due to
family history of prostate cancer may be of benefit (Catalona et al,
2002; Valeri et al, 2002). Familial risk could account for up to 10%
of cases, the proportion being much higher at young ages: 43% in
men aged 55 or less (Carter et al, 1993). The risk of prostate cancer
increases with the number of first or second-degree affected
relatives from about two-fold with a single first-degree relative to
8.8 with a first- and second-degree relative (Carter et al, 1993).
There is little information concerning psychosocial and
behavioural factors having an impact on PSA screening in men
with a familial risk and the existing literature provides contra-
dictory results. Studies have reported that men with a family
history are more likely to have a PSA test (McDavid et al, 2000;
Jacobsen et al, 2004), others found no association between family
history and screening uptake (Taylor et al, 1999; Miller et al, 2001).
Research focusing exclusively on men with a family history of
prostate cancer has suggested that older age (men aged 50 and
over), knowledge of recommended screening frequency, high levels
of education, discussion with a physician, no co-morbidity, and
having more affected relatives are associated with greater screen-
ing uptake (Bratt et al, 1997, 2000; Cormier et al, 2003).
A few studies have investigated psychological morbidity,
screening behaviour and perceived risk in first-degree relatives
(FDRs). In general, psychological morbidity is low in FDRs of
prostate cancer patients. However, high trait anxiety, previous
screening, having a son, perceived high risk, having more than one
affected FDR, and being younger than the affected relative (index
case) have all been associated with greater psychological morbidity
and cancer specific worry (Bratt et al, 2000; Cormier et al, 2002;
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sBeebe-Dimmer et al, 2004). In relation to screening behaviour,
men with higher levels of cancer-specific stress are less likely to
opt for screening (Bratt et al, 2000). Moreover, greater perceived
efficacy regarding screening appears to be associated with
subsequent PSA testing (Vadaparampil et al, 2004).
In addition to some of the contradictory findings in the
literature, the absence of an association between perceived
susceptibility and screening behaviour, runs counter to theoretical
models of health behaviour (Rosenstock, 1974a,b). When inter-
preting these contradictory findings, the methodological difficul-
ties associated with previous studies need to be considered. Many
studies have been limited by a focus on assessing intention to take
a PSA test, instead of measures of actual screening behaviour.
Further, some studies use a retrospective design relying on self-
reports of previous screening as their sole measure of screening
behaviour.
The present study aimed to address some of the limitations of
earlier studies by examining psychosocial attributes, past screen-
ing behaviour, and adherence to a PSA familial screening
feasibility study (FSFS) – a measure of ‘actual’ screening
behaviour.
Five research questions are addressed:
(1) What are the levels of psychological morbidity in a cohort of
men with a family history of prostate cancer entering a familial
PSA screening study?
(2) How is perceived risk of developing prostate cancer related to
psychological morbidity, past screening behaviour and
adherence to a familial screening study?
(3) What is the relationship between perceived barriers, benefits,
and knowledge of PSA screening, perceived susceptibility
to prostate cancer, and psychological morbidity, and is this
related to past screening behaviour or adherence to a
screening programme?
(4) What reasons do men give for entering a familial PSA
screening study and are these related to perceived risk,
psychological morbidity, past screening behaviour, and
screening adherence?
(5) What effect do socio-demographic variables have on psycho-
logical morbidity, perceived barriers, benefits, and knowledge,
and susceptibility, perceived risk, reasons for having test, past




Participants were FDRs of young (cancer diagnosed at 65 years
or less) prostate cancer patients diagnosed within the last 4 years.
Patients were identified through cancer registries, British Associa-
tion of Urological Surgeons (BAUS), the National Cancer Research
Network (NCRN) and participating hospital departments.
(see Melia et al, linked paper in this issue for more details of
recruitment). Eligible FDRs were: (1) aged from 45 to 69 inclusive;
(2) disease free; (3) residing in the UK; (4) able to complete their
questionnaires in English.
Procedure
The recruitment of FDRs into the present study followed on from
their recruitment into a linked PSA FSFS (see Melia et al, 2006).
For the purpose of the study, index cases (ICs) were contacted who
had given details of their FDRs to the FSFS. ICs were sent separate
information on the psychosocial study and asked for their consent
to contact FDRs with regards to participation in the linked
psychosocial study. After ICs gave consent, FDRs were contacted
either by sending further information and a questionnaire or by a
phone call from the researcher, according to the IC’s preference. If
interested in the study, FDRs who had been phoned were then sent
an information pack and questionnaire. All questionnaires were
completed before PSA screening.
The present study was approved by the South London Multi-
centre Research Ethics Committee (MREC 00/1/73) and all ICs and
FDRs gave written informed consent.
Measures
These covered levels of psychological morbidity, barriers, benefits,
and knowledge of PSA screening and perceived susceptibility to
prostate cancer.
Psychological morbidity Four previously validated measures were
used: the General Health Questionnaire 12 (GHQ12), the Impact of
Events Scale (IES), the Cancer Worry Scale-Revised (CWS-R) and
Health Anxiety Questionnaire (HAQ).
The GHQ12 (Goldberg and Hillier, 1979) is an index of
nonspecific psychological morbidity developed for use in com-
munity surveys. A cutoff score of 3 or more indicates psychiatric
‘caseness’; a threshold previously derived from general practice
samples. The IES (Horwitz et al, 1979) assesses intrusive and or
avoidant thoughts modified to relate to risk of prostate cancer
and has been adapted for use with high-risk populations to
reflect subjective stress due to familial cancer experiences; a high
score indicates frequent intrusive/avoidant thoughts about risk
of cancer. The CWS-R (Lerman and Schwartz, 1993) assesses
degree of worry about developing cancer and includes two
additional items: (Watson et al, 1999) assessing frequency of
worry and the extent to which worry is a problem. A high score
indicates greater worry but no clinical cutoff points are currently
available.
Health anxiety and behaviour were assessed using two subscales
from the HAQ (Lucock and Morley, 1996). This 21-item scale
identifies individuals with high levels of concern about their health
and includes four subscales. The two subscales included in the
present study were: (1) Health Worry and Preoccupation and (2)
Reassurance Seeking Behaviour. The other two subscales – Fear of
Illness and Death and Interference with Life – duplicate other
questions asked of the participants or were inappropriate for the
study questions. The abbreviated HAQ uses 11 of the original 21
items with a high score indicating greater anxiety regarding an
individual’s health.
Barriers to PSA screening This was assessed using the Perceived
Barriers Scale (PBS) – a nine-item measure. (Kash et al, 1992;
Watson et al, 1999), covering physical discomfort, fear of
examination, transport to screening clinic, distress caused by
screening, and taking time from work/family/social obligations
to attend. A high score indicates greater perceived barriers to
PSA screening.
PSA screening – benefits, knowledge and susceptibility to prostate
cancer Participants rated statements about managing risk of
prostate cancer and perceived benefits to screening, perceived risk
of prostate cancer, knowledge and a study specific question
assessing participant’s confidence in the PSA test results. The 10
items, derived from Kash et al (1992) and Watson et al (1999) were
assessed using a 4-point scale ranging from ‘strongly agree’ to
‘strongly disagree’. A high score indicates: (1) greater perceived
benefits regarding PSA testing, (2) greater knowledge regarding
PSA screening and prostate cancer, and (3) greater perceived
susceptibility to developing prostate cancer.
Prostate cancer relative risk perceptions Relative perceived risk
of developing prostate cancer was assessed using a single
question: ‘What do you think your risk is compared with the
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saverage man of your age?’ This was rated on a 5-point scale
ranging from ‘Very much lower than average’ to ‘Very much
higher than average’.
Demographic variables Socio-demographic variables included:
age, ethnicity, marital status, education, employment status,
number of children, and religion.
In addition, the assessment included details of past screening
behaviour, present screening behaviour (as part of FSFS), family
history of prostate cancer (e.g. number of relatives diagnosed with
prostate cancer), reason for having a PSA test, impact of being
invited into a PSA screening study, and family history of other
types of cancer.
Statistical methods
A univariate analysis (Pp0.05) comparing men with self-reported
past screening behaviour (digital rectal examination or ‘DRE’ or
PSA) was carried out using w
2 tests of heterogeneity for categorical
data and Independent t-tests (normally distributed) or Man–
Whitney U tests (non-normally distributed) for continuous
variables. Following the results of univariate analysis of psycho-
logical morbidity and screening adherence data, stepwise logistic
regression modelling was carried out in order to identify the
variables that best predicted psychiatric ‘caseness’ (score of 3 or
more on the GHQ12), cancer worry (scores over the sample
median), high subjective stress (total IES scores above the mean
(8.6) reported in a previous study) (Bratt et al, 2003), and
adherence to familial screening (present screening practice as part
of the FSFS). Scores for continuous variables were quartiled and
treated as categorical variables for the purpose of regression
modelling. In addition, due to the low internal consistency of the
perceived benefits, knowledge, and susceptibility subscales – as
measured by a Cronbach’s alpha coefficient of 0.16, 0.40, and 0.31
respectively – these items were entered separately into the
regression models. As the measures of psychological morbidity
were not normally distributed median GHQ, IES and CWS-R
scores will be reported along with their associated interquartile
range (IQR). Mean and standard deviation will be reported for the
IES to enable comparison with previous findings. All analysis was
carried out using a commercially available statistical software
package – SPSS 12.01.
RESULTS
Of 255 ICs (see FSFS reference for details), 155 (61%) consented to
us contacting their male FDRs. This yielded a total of 207 FDRs
who were approached to participate. In total, 62% (n¼128)
consented and filled in baseline measures, 2.5% (n¼5) refused
participation, and 36.5% (n¼74) did not respond to their letter of
invitation.
Table 1 shows the socio-demographic characteristics of the
study sample. The mean age of the sample was 58 years. (s.d.¼6).
Participants were mainly of White ethnicity (95%), employed or
retired (91%), and married or cohabiting (88%). Most were from
social classes I & II (64%) and reported having children (80%) and
35% reported having at least one male child.
In total, 105 men (82%) reported having one brother with
prostate cancer. Two men (1.5%) reported having only a father
with prostate cancer. 19 (15%) reported having a brother and
father with the disease. There were two men (1.5%) who were
unaware as to who exactly had prostate cancer in their family,
despite being in a familial screening study. In addition, 61 men
(48%) reported having a family history of cancer, other than
prostate.
In total, 80 men (63%) reported some previous screening for
prostate cancer, 52 reported PSA, 21 reported a digital rectal
examination (DRE) and seven did not specify type of screening.
Previous screening was associated with having a brother and father
with prostate cancer (w
2
exact, P¼0.003), higher social class (w
2
exact,
P¼0.01), having some form of qualification (w
2
exact, P¼0.001),
agreeing to take part in the familial screening programme to ‘get
more information regarding prostate cancer’ (w
2
exact, P¼0.02),
having a realistic or elevated sense of perceived risk (w
2
exact,
P¼0.001) and higher perceived benefits of PSA screening (t-test,
P¼0.05). There were no significant differences (P¼0.05) in
psychological morbidity (GHQ, IES, CWS-R, HAQ) between those
reporting past screening and those who did not report any
previous screening behaviour.
Psychological morbidity
A total of 18 (14%) men scored above the GHQ12 threshold
for psychiatric ‘caseness’ (median¼0, IQR 0–1). Internal
consistency as measured by Cronbach’s alpha coefficient was
good (0.89).
Univariate analysis revealed that higher IES score (P¼0.04),
being unemployed (P¼0.002), reporting being a little worried or
anxious since invitation to screening (P¼0.05), agreeing to take
part in the familial screening programme ‘for the sake of your
relative who has cancer’ (P¼0.02), family history of cancer other
than prostate (P¼0.03), and higher cancer specific worry
(P¼0.008) were all associated with psychiatric ‘caseness’. The
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smultivariate stepwise regression model revealed that being
unemployed, family history of cancer (other than prostate) and
higher cancer specific worry reliably predict psychiatric ‘caseness’.
The other significant univariate variables were not retained in the
final model (Table 2).
In total, 38 men (30%) scored above the median for subjective
stress on the IES (median¼2, IQR 0–11). The mean for total
IES was 7.59, s.d.¼11.67. Internal consistency for the total IES
as measured by Cronbach’s alpha coefficient was good (0.93).
0.87 and 0.88 for the intrusiveness and avoidance subscales
respectively.
Univariate analysis revealed that higher cancer specific worry
(P¼0.001), psychiatric ‘caseness’ on the GHQ12 (P¼0.04),
finding the psychosocial evaluation itself helpful (P¼0.02),
reporting being a little worried or anxious since invitation to
screening (P¼0.001), higher perceived susceptibility (P¼0.03),
greater perceived barriers (P¼0.02), higher health anxiety
(P¼0.001), were associated with higher IES scores. Multivariate
stepwise regression modelling revealed that higher cancer specific
worry, (P¼0.001) finding the psychosocial evaluation itself
helpful, (P¼0.02) reporting being a little worried or anxious since
invitation to screening (P¼0.01) and higher perceived suscept-
ibility (P¼0.005) reliably predict high IES scores. The other
significant univariate variables were not retained in the final model
(Table 3).
The revised six-item Cancer Worry Scale (CWS-R) yielded good
internal reliability¼0.82. The median for the CWS-R was 8 and the
IQR was 7–10.
Higher health anxiety (P¼0.001), perceived barriers (P¼0.001),
higher perceived susceptibility (P¼0.02), higher perceived knowl-
edge (P¼0.007), higher IES (P¼0.001), psychiatric ‘caseness’
(P¼0.03), having a brother and father with prostate cancer
(P¼0.02), realistic perceived risk compared to an underestimation
of personal risk (P¼0.05), and agreeing to take part in the familial
screening programme ‘for your own sake’ (P¼0.04) were all
associated with higher cancer-specific worry. The multivariate
stepwise regression model revealed that higher health anxiety,
moderate vs low perceived barriers to PSA screening, higher
perceived susceptibility, higher subjective stress scores (IES) and
realistic perceived risk compared to underestimation of risk all
reliably predict higher cancer specific worry regarding prostate
cancer. The other significant univariate variables were not retained
in the final model (Table 4).
Adherence to FSFS
In total, 10 men (8%) failed to adhere to the FSFS. The relationship
between family history, psychosocial and behavioural variables
and adherence to familial screening was examined using w
2 and
logistic regression analysis. A multivariate model was not
constructed as only one variable – past screening behaviour –
reliably predicted (P¼0.04) men’s adherence to familial screening,
that is, men who reported having any kind of screening (DRE or
PSA) for prostate cancer were more likely to adhere to the FSFS
(Table 5).
DISCUSSION
Our goals for this study were to examine the factors relating to
psychological morbidity and screening adherence in a group of
FDRs entering a PSA FSFS.
The findings indicate that FDRs entering the FSFS have quite
low levels of psychological morbidity; 18 men (14%) scored above
the GHQ12 threshold for psychiatric ‘caseness’ and this is within
the normal population range (Jenkins et al, 1997). Psychiatric
‘caseness’ was predicted by family history of cancer other than
prostate, higher cancer specific worry, and being unemployed.
Further, there were moderately high levels of subjective stress
regarding prostate cancer. In total, 30% of men scored high on
subjective stress as measured by the IES (defined as above the
mean IES score (8.6) reported by Bratt et al, 2003). Higher cancer
specific worry, higher perceived susceptibility, and reporting being
a little worried or anxious since invitation to screening were found
to reliably predict high subjective stress regarding prostate cancer.
Interestingly, men reporting that they found the psychosocial
evaluation itself helpful also reliably predicted high subjective
stress as measured by the IES. It is possible that men who have
high levels of subjective stress seem to appreciate an evaluation of
their psychological well being as they enter a screening pro-
gramme, although this requires further investigation.
Levels of cancer-specific worry are lower in this cohort than
those previously reported in other familial cancer studies:
median¼8 compared to scores for a cohort offered BRCA1/2
predictive genetic testing, median¼11 (Foster et al, 2002). This
may be due to gender differences in both reporting both the
experience and reporting of worry (Moynihan, 1998). Cancer-
specific worry was reliably predicted by realistic perceived risk
compared to an underestimation of risk, higher perceived barriers








Family history of cancer other than prostate 6.15 (1.43–26.37) 0.02
Higher cancer specific worry 13.12 (1.96–87.97) 0.008
Being unemployed 16.53 (2.70–101.38) 0.002
Table 4 Stepwise logistic regression model of significant predictors of







Higher subjective stress 10.63 (2.91–38.90) 0.001
Higher perceived susceptibility 12.71 (1.14–141.39) 0.04
Realistic perceived risk vs underestimate 4.08 (1.31–12.66) 0.02
Moderate vs low perceived barriers 7.04 (1.62–30.61) 0.009
Higher health anxiety 14.99 (3.27–68.64) 0.001
Table 3 Stepwise logistic regression model of significant predictors of







Higher cancer specific worry 18.31 (3.70–90.56) 0.001
Higher perceived susceptibility 2.82 (1.37–5.78) 0.005
Finding psychosocial evaluation helpful 4.46 (1.27–15.64) 0.02
A little worried or anxious since invitation 3.74 (1.32–10.59) 0.01







Previous screening behaviour 4.38 (1.08–17.85) 0.04
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sto screening, higher health anxiety, higher subjective stress and
higher perceived susceptibility.
In relation to screening adherence to an FSFS, the present study
found that only previous screening behaviour reliably predicts
adherence to the familial screening study. First-degree relatives
who reported no previous screening were significantly more likely
to drop out of the screening programme, that is, fail to have their
actual PSA test having consented to participate.
In relation to screening behaviour, the present study found a high
(63%) reported level of previous screening in FDRs entering the
FSFS. This was much higher than anticipated and thus motivated an
aposteriori analysis of the association between previous screening
and other psychosocial and socio-demographic variables. Reported
previous screening behaviour was found to be associated with
having more than one FDR with prostate cancer, having a realistic
or elevated sense of perceived risk, higher perceived benefits of PSA
screening, higher perceived susceptibility to prostate cancer, higher
social class and having some form of qualification.
Our findings regarding psychological morbidity concur with
previous research showing that levels of psychological morbidity
in FDRs of prostate cancer patients are not unusually high (Bratt
et al, 2000; Cormier et al, 2002), although a minority (30%) report
some symptoms of stress as assessed by the Impact of Evens Scale,
which assessed specific intrusive thoughts or avoidant reactions to
concern about risk of prostate cancer. Therefore, it is less that
these FDRs have higher than average levels of psychiatric caseness
and more that they have some level of stress, in a minority, specific
to prostate cancer risk. How such concerns might be addressed
requires some consideration. In addition, the current study
reinforces previous findings regarding the importance of health
anxiety, perceived risk, and having more than one affected FDR in
relation to psychological morbidity (Bratt et al, 2000; Cormier
et al, 2002; Beebe-Dimmer et al, 2004).
Our finding regarding the importance of employment status in
relation to psychological morbidity is in keeping with previous
findings suggesting the importance of work to both men’s mental
health and health behaviours (Lahelma, 1992; Artazcoz et al, 2004).
The present study found that increased reporting of perceived
barriers to PSA screening such as taking time off work is
associated with higher levels of cancer-specific worry. Some
investigation of the specific methods that might allow a reduction
in barriers to screening in those men who may otherwise see a
benefit to screening is indicated.
Cormier et al (2002) found a significant association between
having a son and psychological morbidity; however, we found no
such relationship. This inconsistency may be explained by Cormier
et al’s focus on worry about genetic susceptibility and genetic
testing. Those measures explicitly assessed the amount of worry
over genetic heritability with regards to participants’ children. This
is distinctly different from the measures of psychological
morbidity in the present study, which focused on the participants’
personal cancer worry.
With respect to screening behaviour, Vadaparampil et al (2004)
found that previous screening predicted participation in subse-
quent PSA screening. However, unlike the present study, the
authors found participation to be related to older age (X50),
annual income (XUS$40000) and higher levels of self-efficacy.
Both studies show that previous screening behaviour predicts
present screening behaviour. However, the present study did not
measure levels of income or self-efficacy, although we did collect
data on social class/occupation, and this was not found to be
associated with screening adherence. Inconsistencies may also be
due to methodological differences including the time frames and
context in which the screening took place. Our study reports
screening as part of the FSFS (adherence) while Vadaparampil et al
(2004) conducted a retrospective study in which they contacted
FDRs 14 months after their initial assessment to find out if they
had undertaken PSA screening. Only one previous study has
investigated adherence to a familial PSA screening programme
(Roumier et al, 2004). The authors found that younger men, those
who were more anxious and men with more than one affected FDR
were less likely to adhere to a familial screening program. The
present study failed to confirm such associations. However,
Roumier and co-workers examined the adherence of FDRs to a
second and third annual PSA screening test, after an initial test, in
contrast to our study, which examined adherence to a one off PSA
test after agreeing to take part in a FSFS.
Our aposteriori analyses regarding the association between
previous screening and other psychosocial and socio-demographic
variables are consistent with findings reported elsewhere (Bratt
et al, 1997, 2000; Cormier et al, 2003; Vadaparampil et al, 2004).
However, unlike previous studies (Bratt et al, 2000; Miller et al,
2001; Vadaparampil et al, 2004), we found no association between
age and past screening behaviour of FDRs. This inconsistency may
be due to differences in the status and awareness of PSA screening
and variations in endorsement by health care providers, both of
which can be seen to vary between the UK and other countries
such as the US where for the latter, the culture of PSA screening is
more widespread (O’Dell et al, 1999).
The present study found that agreeing to take part in the familial
screening programme to ‘get more information regarding prostate
cancer’ was also associated with previous screening behaviour. This
suggests that there are cohorts of men who are actively engaged in
help-seeking behaviours. For example, men may want to find out
about new developments. Alternatively, men may not have been
given sufficient information when they were screened previously. It
may be useful for health care providers to highlight information
provision as a priority when attempting to implement a screening
programme, whether a man has had previous screening or not.
The present study offers some insights into FDRs’ screening
behaviour, psychological morbidity and adherence to a familial
screening programme, but some study limitations must also be
taken into consideration. Due to the small number of people that
did not adhere to screening (n¼10), it is likely that our model to
predict adherence is underpowered, although the findings are
consistent with previous research (Roumier et al, 2004).
Our response rates from ICs and FDRs were 61 and 62%,
respectively. The men recruited to the present study were only a
percentage (75%) of those men who had consented to the FSFS. Our
data may not extrapolate more broadly as the sample consisted of
predominantly Caucasian men in upper social class groups. Black
(African and African-Caribbean ethnicity) men did not form part of
the sample for either the present study or the FSFS despite the
evidence that these men may be at an additional increased risk of
prostate cancer (Grulich et al, 1992; Chinegwundoh et al,2 0 0 3 ) .A s
suggested by other research, ‘traditional’ methods of recruitment
may need to be changed if men from these groups are to be
recruited into similar studies (Odedina et al, 2002, 2004). Under-
standing why there is a relatively low response rate of men in
general into research screening is needed. It is conceivable that
nonparticipants are anxious or not receptive to research or
particular methods of screening such as DRE (Odedina et al,
2004). Aspects of masculinity such as appearing weak rather than
strong and healthy, may be impacting on participation in screening
as shown elsewhere in relation to health practices (Connell, 1995;
Moynihan, 1998; Courtenay, 2000), and some of these men may
require targeted counselling. The uncertainty surrounding treat-
ment and screening for prostate cancer may have acted as a
possible barrier to screening in some men (Chapple et al, 2002).
In conclusion, although levels of psychological morbidity appear
to be quite low in the men attending the prostate familial screening
programme, certain factors such as health anxiety, cancer worry,
unemployment and perceived risk do impact on their state of well
being. Previous screening behaviour predicts current and likely
future uptake of screening. Thus, eliciting men into screening
(where this may be beneficial) in the first place remains a
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schallenge. Further information on PSAS screening costs–benefits
is likely to be helpful both in facilitating decision-making and
assuaging specific cancer worry. More research is needed on
decision making in PSA screening uptake before it is possible to
provide specific recommendations on service development.
Although reasons cannot be provided, the finding that men
without a previous history of testing are more likely to be those
who do not adhere to familial screening, despite consenting,
suggests that this group may also require additional information.
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